Farhan Siddiqui, MD
Pulmonary Disease · Spartanburg, SCNPI 1447461579
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,179 of the $24,452 with a category attached, or 66.2%. It is spread thinly across 59 manufacturers, the largest accounting for just 18.8%. 2025 is the largest year on record at $9,114, 6.4 times the $1,417 reported in 2019.
Across 837 payments — averaging $29.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- AstraZeneca$4K
- GSK$2K
- Modernatx, Inc.$2K
- Inspire Medical Systems, Inc.$1K
- Boehringer Ingelheim$1K
- plus $10K from 53 others
Across 2,092 payments — averaging $4228.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$3.1M
- Seqirus USA Inc$1.2M
- Pfizer$1.1M
- Vertex$794K
- Eli Lilly$622K
- AstraZeneca$440K
- plus $1.6M from 12 others
What the payments were for
- Travel & lodging$3,99716%
- Food & beverage$16,17966%
- Education$4,09717%
- Gifts$1781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,504
- Inspire$1,020
- FASENRA$913
- TEZSPIRE$833
- BREZTRI$751
- AIRSUPRA$355
- FARXIGA$338
- MeMed-BV$178
- TAGRISSO$161
- BEVESPI AEROSPHERE$156
- AQUADEX SMARTFLOW CONSOLE$154
- Monarch Platform$113
How this compares
$24,452 in reported general payments places this provider in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 516 | $392,165 |
| Dupixent PenDupilumab | 57 | $267,835 |
| NucalaMepolizumab | 43 | $163,524 |
| OfevNintedanib Esylate | 11 | $143,248 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 158 | $119,334 |
| AdempasRiociguat | 12 | $101,652 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $44,416 |
| Dupixent SyringeDupilumab | 12 | $44,089 |
| SymbicortBudesonide/Formoterol Fumarate | 99 | $36,142 |
| Spiriva RespimatTiotropium Bromide | 44 | $33,800 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $33,068 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 43 | $26,416 |
| Incruse ElliptaUmeclidinium Bromide | 41 | $15,228 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 339 | $12,537 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 19 | $11,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,525 | $652,177747 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,039 | $214,761117 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $4,216 | $155,476257 claims |
| BayerAdempas | $164 | $101,65212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Spartanburg
- Joseph BosciaSpartanburg$701K
- David ErbSpartanburg$12K
- Charles FogartySpartanburg$10K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.